[{"id":"ea1f50a5-a6a7-4a19-a2ae-69a94c131980","acronym":"","url":"https://clinicaltrials.gov/study/NCT05388695","created_at":"2022-05-24T11:54:05.541Z","updated_at":"2024-07-02T16:35:57.653Z","phase":"Phase 1","brief_title":"To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors","source_id_and_acronym":"NCT05388695","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" CD20 • CD22","pipe":" | ","alterations":" CD20 positive • CD19 positive • CD22 positive • CD19 positive + CD20 positive","tags":["CD20 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD19 positive • CD22 positive • CD19 positive + CD20 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/08/2022","start_date":" 04/08/2022","primary_txt":" Primary completion: 03/30/2025","primary_completion_date":" 03/30/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2023-01-13"}]